Dr. Stéphane Prost CML Chronic Myeloid Leukemia
Atomic Energy and Alternative Energies Commission | CEA · Institut de Biologie François Jacob, Centre de Recherche de Fontenay-aux-Roses
ARTICLES
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
February 10, 2014, PublMed
Erosion Of The Chronic Myeloid Leukemia Stem Cell Pool By PPARγ Agonists.
November 15, 2013, Blood
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
February 10, 2014, PublMed
Erosion Of The Chronic Myeloid Leukemia Stem Cell Pool By PPARγ Agonists.
November 15, 2013, Blood